Ribo

Kunshan RiboCure Pharmaceutical Science and Technology Co., Ltd. is an ophthalmic innovative drug developer. The company's main products include QPI-1007, which is currently undergoing clinical trials, including a Phase III clinical trial for the treatment of NAION (non-arteritic anterior ischemic optic neuropathy) and a Phase IIa exploratory trial for the treatment of glaucoma. NAION is a serious eye disease for which there are currently no treatment options, and acute angle-closure glaucoma is also a condition with no effective treatments available other than surgical intervention. Glaucoma is one of the leading causes of blindness.